stockrow
Friday 6 November 2026
Export MDLN’s income statement to Excel — free account
Medline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.
- Revenue
- +14.1%
- Free cash flow
- +916.1%
- Total debt
- −23.7%
Quarter to September 2026, against a year earlier
39.42
0.34
−0.86%
Follow MDLN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+4 more quarters Free account |
50.68 | 50.68 | 50.68 | 50.68 |
P/S ratio |
0.00 | 1.27 | 1.14 | 0.99 | |
P/FCF ratio |
10.06 | 15.96 | 14.67 | 9.81 | |
P/Operating CF |
19.51 | 88.46 | 47.27 | 29.67 | |
P/B ratio |
1.76 | 1.88 | 1.77 | 1.57 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.00 | 1.63 | 1.47 | 1.31 | |
EV/EBITDA |
0.00 | 4.58 | 4.35 | 4.01 | |
EV/Operating CF |
10.16 | 15.41 | 14.24 | 10.35 | |
EV/FCF |
13.20 | 20.48 | 18.97 | 13.00 | |
Quick Ratio |
2.20 | 2.33 | 2.34 | 1.21 | |
Current Ratio |
4.29 | 4.41 | 4.33 | 4.04 | |
Net Debt/EBITDA |
1.36 | 15.05 | 14.91 | 0.00 | |
Debt/Assets |
32.64% | 32.22% | 31.96% | 31.31% | |
Debt/Equity |
0.65 | 0.65 | 0.66 | 0.65 | |
Asset Turnover |
0.00 | 0.76 | 1.51 | 0.81 | |
Operating CF/Net income |
9.58 | 3.19 | 11.92 | 5.26 | |
Capex/Depreciation |
(0.42) | (0.36) | (0.41) | 0.00 | |
Interest Coverage |
— | 3.10 | 3.32 | 4.24 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 16.70% | 16.85% | 16.03% | |
Intangible Assets out of Total Assets |
0.57 | 0.56 | 0.55 | 0.53 | |
Share Based Compensation of Revenue |
0.00% | 0.31% | 0.38% | 0.37% | |
Graham Net Nets |
(0.25) | (0.23) | (0.25) | (0.27) | |
Graham Number |
0.00 | 0.00 | 0.00 | 18.46 | |
Earnings Yield |
1.97% | 1.97% | 1.97% | 1.97% | |
Free Cash Flow Yield |
9.94% | 6.27% | 6.82% | 10.20% | |
Revenue per Share |
9.61 | 8.98 | 8.97 | 8.96 | |
Operating CF per Share |
2.15 | 0.50 | 0.83 | 1.17 | |
Capex per Share |
(0.55) | (0.12) | (0.13) | (0.16) | |
Free Cash Flow per Share |
1.60 | 0.39 | 0.70 | 1.01 | |
Cash per Share |
2.39 | 2.73 | 3.12 | 0.00 | |
Shareholders Equity per Share |
23.81 | 23.63 | 22.26 | 22.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
23.81 | 23.63 | 22.26 | 22.12 | |
Free Cash Flow |
1,297.00 | 316.00 | 604.00 | 884.00 | |
Working Capital |
8,189.00 | 8,644.00 | 9,032.00 | 9,524.00 | |
Capital Expenditures |
(447.00) | (96.00) | (111.00) | (141.00) | |
Net Current Asset Value |
(8,519.00) | (8,485.00) | (8,531.00) | (8,139.00) | |
EV/EBIT |
0.00 | 4.97 | 4.73 | 4.43 | |
Capex to Sales |
0.06 | 0.01 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 3.87 | 3.66 | 3.34 | |
| Other line items | |||||
Average Receivables |
— | — | — | 3,506.50 | |
Average Payables |
— | — | — | 1,039.00 | |
Average Inventory |
— | — | — | 4,631.00 | |
Average Assets |
19,242.00 | 37,496.00 | 19,675.00 | 38,078.00 | |
Average Common Equity |
— | — | — | 17,772.00 |
Columns are period end dates · fundamentals updated 4 Nov 2026